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In this issue, Heist et al.1 present experience from a phase I to II trial of a combinationof topotecan and targeted drug AT-101 for patients with small cell lung cancer in
progression after first-line chemotherapy. Although the trial did not include a control
group and the study population was relatively small, it nevertheless seems that this
combination of a targeted drug and chemotherapy is not superior to chemotherapy alone.
A similar conclusion may be derived from five other studies on advanced non-small
cell lung cancer with a total of more than 5000 patients. Two trials (INTACT 1 and
INTACT 2) tested chemotherapy alone or in combination with gefitinib2,3 and the other
two (TRIBUTE and TALENT) tested chemotherapy with or without erlotinib.4,5 In all
four trials, adding a tyrosine kinase inhibitor to chemotherapy did not prolong the time to
progression or overall survival. The fifth study is the recently published FLEX trial in
which chemotherapy was given with or without cetuximab.6 Addition of cetuximab led to
moderate yet statistically significant prolongation of overall survival. However, there was
an important difference in the duration of the treatment between the two arms: patients in
the chemotherapy-only arm stopped all anticancer treatment after a maximum of 4
months, whereas the cetuximab arm continued with the targeted drug until progression. A
close look at the data reveals overlapping survival curves during the first 6 months and
their separation only after 8 months of treatment. Therefore, it remains uncertain whether
the combination is truly superior to chemotherapy alone. It may well be that the advantage
of the cetuximab arm in the FLEX trial was due to the benefit of prolongation of the
primary treatment. In other words, it is not the superiority of the combination but longer
duration of primary treatment that led to better survival—a phenomenon seen also in
positive trials of maintenance or early second-line treatment with gemcitabine, pem-
etrexed, or erlotinib.7–9
After negative experience from these six trials, should we continue with efforts to
combine chemotherapy and targeted drugs or should we abandon any further research in
this direction? To approach this question, we have to see what all six trials have in
common and try to answer why they failed. All six trials are similar in one parameter: they
applied chemotherapy and targeted drugs simultaneously. Schedules that apply chemo-
therapy and targeted drugs simultaneously ignore one crucial aspect: potential antagonism
between the two classes of drugs. Sensitivity to targeted drugs may well push tumor cells
to the dormant phases of the mitotic cycle and render them resistant to classic cytotoxic
agents. If this is true, then negative results from simultaneous use of cytotoxic drugs and
targeted agents do not come as a surprise.
Time separation between chemotherapy and targeted drugs is an approach that
avoids the aforementioned antagonism between the two classes of drugs. An additional
advantage of such an intermittent schedule is prevention of tumor repopulation that occurs
during the gap between individual applications of chemotherapy.10 In vitro research has
clearly demonstrated that schedules with different timing of chemotherapy and of targeted
drugs lead to their synergistic or antagonistic antitumor activity.11–13 Preliminary prom-
ising experience from clinical trials conducted in United States,14 Hong Kong,15 and
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Slovenia (M. Zwitter, unpublished data) supports the concept
of intermittent schedules. Deeper understanding of general
tumor biology, the characteristics of each individual tumor,
and optimal timing of our interventions should lead to fewer
disappointments in future clinical research.
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